Guardant Health 8-K Signals Upcoming Financial Disclosure
Ticker: GH · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1576280
| Field | Detail |
|---|---|
| Company | Guardant Health, Inc. (GH) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: financial-disclosure, regulation-fd, corporate-update
TL;DR
**Guardant Health just filed an 8-K, signaling upcoming financial results and disclosures.**
AI Summary
Guardant Health, Inc. filed an 8-K on January 8, 2024, indicating that it will be disclosing information related to its 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure'. This filing signals that the company is likely to release important financial updates, potentially including preliminary earnings or operational metrics, which could impact investor perception of its current performance and future outlook. Investors should pay close attention to any subsequent announcements from Guardant Health, Inc. as these disclosures could significantly influence the stock's price.
Why It Matters
This filing alerts investors that Guardant Health is preparing to release significant financial information, which could reveal the company's recent performance and future prospects, directly affecting its stock valuation.
Risk Assessment
Risk Level: medium — The filing itself is administrative, but the upcoming financial disclosures it signals carry inherent market risk depending on the content.
Analyst Insight
A smart investor would monitor Guardant Health's news channels closely for the actual financial disclosures that this 8-K foreshadows, as those will contain the actionable information regarding the company's performance.
Key Players & Entities
- Guardant Health, Inc. (company) — the registrant filing the 8-K
- January 8, 2024 (date) — date of earliest event reported and filing date
- Delaware (company) — state of incorporation for Guardant Health, Inc.
- 001-38683 (dollar_amount) — Commission File Number
- 45-4139254 (dollar_amount) — IRS Employer Identification No.
- 3100 Hanover Street, Palo Alto, California 94304 (company) — address of principal executive offices
- 855-698-8887 (dollar_amount) — registrant's telephone number
- GH (company) — trading symbol for Guardant Health, Inc.
- The Nasdaq Global Select Market (company) — exchange where Guardant Health, Inc. common stock is registered
FAQ
What is the primary purpose of Guardant Health, Inc.'s 8-K filing on January 8, 2024?
The primary purpose of Guardant Health, Inc.'s 8-K filing on January 8, 2024, is to report on 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure', indicating upcoming financial information releases.
What is the trading symbol and the exchange where Guardant Health, Inc. stock is registered?
Guardant Health, Inc.'s trading symbol is GH, and its common stock is registered on The Nasdaq Global Select Market.
What is the business address of Guardant Health, Inc. as stated in the filing?
The business address of Guardant Health, Inc. is 3100 Hanover Street, Palo Alto, California 94304.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is January 8, 2024.
Under which items of the SEC regulations is Guardant Health, Inc. making disclosures in this 8-K?
Guardant Health, Inc. is making disclosures under 'ITEM INFORMATION: Results of Operations and Financial Condition' and 'ITEM INFORMATION: Regulation FD Disclosure' in this 8-K.
Filing Stats: 556 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-01-08 16:17:33
Key Financial Figures
- $0.00001 — ange on which registered Common Stock, $0.00001 par value per share GH The Nasdaq G
Filing Documents
- d710991d8k.htm (8-K) — 24KB
- d710991dex991.htm (EX-99.1) — 19KB
- g710991dsp2.jpg (GRAPHIC) — 17KB
- g710991g0108020015408.jpg (GRAPHIC) — 1KB
- 0001193125-24-004446.txt ( ) — 188KB
- gh-20240108.xsd (EX-101.SCH) — 3KB
- gh-20240108_lab.xml (EX-101.LAB) — 17KB
- gh-20240108_pre.xml (EX-101.PRE) — 11KB
- d710991d8k_htm.xml (XML) — 3KB
02
Item 2.02. Results of Operations and Financial Conditions. On January 8, 2024, Guardant Health, Inc. (the "Company") announced certain preliminary unaudited financial information for the quarter and full year ended December 31, 2023. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
01
Item 7.01. Regulation FD Disclosure. The Company will post the presentation that it will present at the 2024 J.P. Morgan Healthcare Conference on January 8, 2024 to the Company's website, www.guardanthealth.com, on the "Events & Presentations" page under the "Investors" tab. The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release of Guardant Health, Inc., dated January 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GUARDANT HEALTH, INC. Date: January 8, 2024 By: /s/ Michael Bell Michael Bell Chief Financial Officer (Principal Accounting Officer and Principal Financial Officer)